Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

Why Is Horizon Therapeutics (HZNP) Up 38.3% Since Last Earnings Report?

Horizon (HZNP) holds preliminary discussions with Amgen, Sanofi and Janssen, a subsidiary of J&J, seeking an offer for its acquisition by any one of the pharma giants. Shares rise.

Horizon (HZNP) Up on Initial Talks of Buyout by Pharma Giants

Three big drugmakers could be interested in acquiring Horizon.

Why Horizon Therapeutics Stock Is Skyrocketing Today

Horizon Therapeutics (NASDAQ: HZNP ) stock is rising higher on Wednesday following reports that the company is considering a buyout. According to a news release from the company, it has engaged in early discussions that could result in a deal with one of three pharmaceutical companies.

Why Is Horizon Therapeutics (HZNP) Stock Up 30% Today?

Shares of Horizon Therapeutics Plc HZNP, +27.12% rallied 32.8% in premarket trading on Wednesday, the day after the company confirmed to The Wall Street Journal that it's in early talks to be acquired by Amgen Inc. AMGN, -0.87% , Johnson & Johnson JNJ, -0.50% , or Sanofi SNY, -3.12% in a deal that could be worth up to $20 billion. Horizon put a news release on Tuesday night confirming the preliminary acquisition discussions with the three companies.

Horizon's stock jumps 32% as the company confirms takeover interest from pharma giants

Shares of Horizon surged after the company announced it is in "highly preliminary" discussions with three big pharma companies about a potential takeover. In the article, I discuss a potential deal value, assuming a deal is to be consummated.

Horizon Therapeutics Draws Big Pharma Interest

Horizon Therapeutics PLC (NASDAQ:HZNP) is surging this morning, last seen up 29.6% at $102.10, following news that the company is reconsidering possible bids from Amgen (AMGN), Sanofi (SASY), and Johnson & Johnson's (JNJ) unit Janssen Global Services.

Horizon Therapeutics Reconsiders Several Big Buyout Bids

Horizon said it was in talks with Amgen, Janssen Global Services and Sanofi.

Horizon Therapeutics Surges on Takeover Talk. It Could Be 2022's Largest Healthcare Deal.

Amgen

Johnson & Johnson

Sanofi

Horizon said Tuesday it's considering potential offers from three Big Pharma stalwarts, sending HZNP stock soaring more than 30% after hours. The post Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi appeared first on Investor's Business Daily.

Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi

Drugmaker Horizon Therapeutics PLC is fielding takeover interest, according to people familiar with the matter, as large pharmaceutical companies compete for fast-growing medicines to fuel sales.

Pharma giants take interest in acquiring Horizon Therapeutics

DUBLIN--( BUSINESS WIRE )--The Board of Horizon Therapeutics plc (Nasdaq: HZNP) (“Horizon” or the “Company”) confirms that it is engaged in highly preliminary discussions with Amgen Inc., Janssen Global Services, LLC and Sanofi (each a "Possible Offeror") which may or may not lead to an offer being made for the entire share capital of the Company. There can be no certainty that any offer will be made for the Company.

Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer

The drugmaker recently had a market value close to $18 billion as big pharmaceutical companies rely on acquisitions to expand sales.

Horizon Therapeutics Fields Takeover Interest from Pharma Giants

Xeris Biopharma Holdings

Technology-based biopharma company Xeris (US:XERS) is set to boost its revenue with an upfront cash payment from a research collaboration and option agreement that was secured with mid-cap pharma Horizon Therapeutics (US:HZNP).

New Research Partnership With Horizon Therapeutics Could Be the Next Revenue Catalyst for Xeris

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Horizon Therapeutics (HZNP) is a Top-Ranked Value Stock: Should You Buy?

Xeris Biopharma Holdings (NASDAQ:XERS) said it has entered into a research collaboration and option agreement with Horizon Therapeutics PLC.  Under the terms of the agreement, Xeris will use its proprietary formulation technology platform, XeriJect, to develop an ultra-concentrated, ready-to-use, subcutaneous injection of teprotumumab and Horizon will have an option to license the Xeris technology.

Xeris Biopharma inks research collaboration and option agreement with Horizon Therapeutics

CHICAGO--( BUSINESS WIRE )--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (Nasdaq: HZNP). Under the terms of the agreement, Xeris will use its proprietary formulation technology platform, XeriJect™, to develop an ultra-concentrated, ready-to-use, subcutaneous injection of teprotumumab and Horizon will have an option to license the Xeris technology. Teprotumumab is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of Thyroid Eye Disease (TED) – a serious, progressive and potentially vision-threatening rare autoimmune disease. Teprotumumab-trbw is known as TEPEZZA® in the United States. Xeris will receive an upfront payment, and may be entitled to receive development milestones, regulatory milestones, and sales-based milestones, as well as royalties based on future sales if the commercial license option is exercised. Specific financial terms of the agreement were not disclosed.

Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab

DUBLIN--( BUSINESS WIRE )--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed enrollment of its Phase 3 clinical trial (OPTIC-J) in Japan evaluating TEPEZZA for the treatment of active Thyroid Eye Disease (TED).

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)

DUBLIN--( BUSINESS WIRE )--Horizon Therapeutics plc today announced that it has entered a multi-year scientific collaboration with Johns Hopkins University School of Medicine to identify new disease targets and develop therapies for patients with serious autoimmune and inflammatory conditions. The initial focus is the emerging field of immunometabolism, the study of metabolic processes in the body, that when dysregulated, can drive autoimmunity and inflammation. This is the first project in the collaboration, with additional projects to follow.

Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences in November: Stifel 2022 Healthcare Conference Date: Tuesday, Nov. 15, 2022 Presentation Time: 1:15 p.m.

Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Month 12 data from the MIRROR randomized controlled trial of KRYSTEXXA® (pegloticase) injection with methotrexate will be featured in Plenary I as part of the American College of Rheumatology Convergence 2022.

Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that indicate KRYSTEXXA (pegloticase) injection with weekly oral methotrexate effectively treats uncontrolled gout without compromising kidney function.

Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease

Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2022. The company raises net sales guidance for 2022.

Horizon's (HZNP) Q3 Earnings & Revenues Surpass Estimates

The company released encouraging year-end guidance.

Why Horizon Therapeutics' Shares Rose 11.32% on Wednesday

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP ) Q3 2022 Results Conference Call November 2, 2022 8:00 AM ET Company Participants Tina Ventura - Senior Vice President, Chief Investor Relations Officer Tim Walbert - Chairman, President and Chief Executive Officer Liz Thompson - Executive Vice President, Research & Development Aaron Cox - Executive Vice President and Chief Financial Officer Andy Pasternak - Executive Vice President, Chief Strategy Officer Conference Call Participants Chris Schott - JPMorgan Annabel Samimy - Stifel Madhu Kumar - Goldman Sachs Jason Gerberry - Bank of America Ken Cacciatore - Cowen David Risinger - SVB Securities LLC David Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Equity Research Amy Li - Jefferies Operator Good morning, and thank you for standing by. Welcome to the Horizon Therapeutics plc Third Quarter 2022 Earnings Conference Call.

Horizon Therapeutics Public Limited Company (HZNP) Q3 2022 Earnings Call Transcript

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 25% and 4.10%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Horizon Pharma Stock (HZNP)